Targeting FAP-positive CAF in murine models has been shown to enhance anti-tumor immunity in several solid tumor models; a FAP-DNA vaccine induced CD8+ and CD4+ T-cells and synergised with other tumor antigen-specific DNA vaccines to enhance anti-tumor immunity (Duperret et al., 2018). This evidence concerns the gene CD8A and neoplasm.